Immunosuppression by micromolecular fibrinogen degradation products in cancer.
D000230:Adenocarcinoma / Q000276:immunology; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D001943:Breast Neoplasms / Q000276:immunology; D002277:Carcinoma / Q000276:immunology; D005338:Fibrin Fibrinogen Degradation Products / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents; D007680:Kidney Neoplasms / Q000276:immunology; D007945:Leukemia, Lymphoid / Q000276:immunology; D008103:Liver Cirrhosis / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology; D012004:Rectal Neoplasms / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology
D005338:Fibrin Fibrinogen Degradation Products; D007166:Immunosuppressive Agents